Full Text View
Tabular View
No Study Results Posted
Related Studies
Amyotrophic Lateral Sclerosis (ALS) Tissue Donation Program
This study is currently recruiting participants.
Study NCT00716131   Information provided by Drexel University
First Received: July 14, 2008   Last Updated: April 6, 2009   History of Changes

July 14, 2008
April 6, 2009
April 2007
December 2013   (final data collection date for primary outcome measure)
 
 
Complete list of historical versions of study NCT00716131 on ClinicalTrials.gov Archive Site
 
 
 
Amyotrophic Lateral Sclerosis (ALS) Tissue Donation Program
ALS Tissue Donation Program

Despite significant progress in the identification of mechanisms involved in motor neuron degeneration in Amyotrophic Lateral Sclerosis (ALS) and other motor system diseases, the actual pathogenesis and cause of these diseases remains unknown. Effective treatment of these diseases are dependent on the elucidation of their causes. The availability of diseased and control human tissues will be a critical resource for this research progress. . Samples of serum, spinal fluid, and urine from patients with motor system diseases can be used to study biochemical and genetic differences compared to tissues of neurologic disease controls and normal controls. Furthermore, the availability of autopsied CNS, PNS, as well as other tissues from patients with ALS or suspected ALS are useful for current and future research studies into the disease. Therefore, we propose to institute a Tissue Bank containing blood, urine, and cerebrospinal fluid donated from not only ALS and other motor neuron disease patients, but also those with other neurologic diseases and normals whose tissue can be used as controls. In addition there will be an autopsy band for post-mortem specimens of ALS and other motor neuron disease patients. Each specimen, whether from a living patient or autopsy will be de-identified and accompanied by a standard set of clinical information collected from the medical records in order that each specimen is characterized with the relevant clinical information to maximize the usefulness of the specimens.

Once established, this tissue bank will provide a resource in which a large number of samples will be readily available and expedite research by circumventing the delays in collecting specimens prospectively. These specimens will be used for research in the ALS Center of Hope at Drexel University College of Medicine and shared with any outside investigator with a valid IRB approved protocol.

 
 
Observational
Case Control, Cross-Sectional
  • Amyotrophic Lateral Sclerosis
  • Cerebrospinal Fluid
  • Neurodegenerative Disease
  • Motor Neuron Disease
 
  • Diagnosed with ALS or other motor system disorder including PLS, Bulbar Palsy or Motor neuropathy
  • Diagnosed with other chronic neurologic illnesses (Alzheimers, multiple sclerosis, migraines, etc)
  • Normal Controls
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Recruiting
300
December 2014
December 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosed with ALS or other motor system disorder including PLS, Bulbar Palsy or Motor neuropathy
  • Diagnosed with other chronic neurologic illnesses (Alzheimers, multiple sclerosis, migraines, etc)
  • Normal Controls
  • In the case of spinal fluid collection, the patient will be undergoing a diagnostic lumbar puncture as part of the work-up

Exclusion Criteria:

  • Any person with a non-neurologic chronic and poorly controlled systemic illness
Both
18 Years and older
Yes
 
United States
 
NCT00716131
Terry Heiman-Patterson, MD, MDA/ALS Center of Hope
Internal-16827
Drexel University College of Medicine
MDA/ALS Center of Hope
 
Drexel University
April 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP